Liver
- First-Line Pembrolizumab Failed to Improve PFS, OS in Advanced HCC
- Psychotherapy Linked to Reduced Risk for Liver Disease in Alcohol Use Disorder
- Camrelizumab Plus Rivoceranib Deemed New First-Line Option for Unresectable HCC
- Increasing BMI Linked to Higher Risk for Liver and Biliary Tract Cancers
- Predictors for Survival After Liver Transplantation in NASH
- Therapeutic Peptide Granted Orphan Drug Status for Hepatorenal Syndrome
- Alcohol-Related Cirrhosis Associated With Increased Fracture and Mortality Rate
- Liver Transplantation Survival Rates Lower in Recipients Aged 70 Years and Older
- Global Prevalence of Nonalcoholic Fatty Liver Disease on the Rise
- Higher Prevalence of AF With Liver Stiffness, Not Fatty Liver Disease
- Mediterranean Diet Remains Effective Treatment for NAFLD
- Prenatal Exposure to Endocrine-Disrupting Chemicals Linked to Liver Injury
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
